Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to...

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment ↗

October 03, 2026

Performance

52-Week Range 28.9% below 52-week high

29.23

10.8352W Low 41.1452W High

1 Week

26.201W Low 29.231W High

Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) traded between $10.83 and $41.14 over the past 52 weeks and last traded at $29.23, 28.9% below its 52-week high. Over the past week it ranged between $26.20 and $29.23.

Past 12 Months

+8.1%

-9.8%

+58.0%

+66.2%

+156.0%

+90.2%

1W +$2.20

1M -$3.16

3M +$10.73

6M +$11.64

YTD +$17.81

1Y +$13.86

AMLX was +90.2% over the past year, +66.2% over six months, +156.0% year to date, +8.1% in the last week.

12 Months vs Market

AMLX

+90.2%

DIA

+12.6%

SPY

+15.1%

QQQ

+18.8%

IWM

+11.6%

Over the past 12 months AMLX returned +90.2% versus DIA (Dow) +12.6%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +18.8% and IWM (Russell 2000) +11.6%.

Volume & Liquidity 0.25× 3-mo avg

Today 581,986 3-mo avg 2.3M

1.2M

1.3M

2.3M

1.9M

YTD

1.6M

AMLX most recently traded 581,986 shares against a 3-month average daily volume of 2.3M.

More News

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

September 23, 2026

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

September 08, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗

August 06, 2026

Via Chartmill

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? ↗

September 01, 2026

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week ↗

August 21, 2026

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

August 19, 2026

Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗

August 18, 2026

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

August 18, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 18, 2026

Via Benzinga

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗

August 18, 2026

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 18, 2026

Via Benzinga

August 18, 2026

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 06, 2026

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

August 03, 2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 23, 2026

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 08, 2026

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026